Prescription medicine
Human vaccinia virus immune globulin Brand names: Cnj
Human vaccinia virus immune globulin (Cnj) is a prescription medicine. No generic is listed in FDA's NDC Directory.
- No generic listed
- Boxed warning
Check it at the source: the human vaccinia virus immune globulin FDA label on DailyMed (effective December 16, 2025); every human vaccinia virus immune globulin label on DailyMed.
Highlights of the record
FDA label of December 16, 2025; NDC Directory, Drugs@FDA and Orange Book, October 8, 2026
INTERACTIONS WITH GLUCOSE MONITORING SYSTEMS.
Blood glucose measurement in patients receiving VIGIV must be done with a glucose-specific method (monitor and test strips) to avoid interference by maltose contained in VIGIV. Glucose dehydrogenase pyrroloquinolinequinone (GDH-PQQ) or glucose-dye-oxidoreductase method (monitor and test strips) must not be used for blood glucose testing in patients receiving VIGIV, since maltose in IGIV products has been shown to give falsely high blood glucose levels in these testing systems. This could result in the inappropriate administration of insulin, resulting in life-threatening hypoglycemia. Cases of true hypoglycemia may go untreated if the hypoglycemic state is masked by falsely elevated glucose readings. Carefully review the product information of the blood glucose testing system, including that of the test strips, to determine if the system is appropriate for use with maltose-containing parenteral products [see 5.3 Blood Glucose Monitoring ]. WARNING: INTERACTIONS WITH GLUCOSE MONITORING SYSTEMS See full prescribing information for complete boxed warning. Blood glucose measurement in patients receiving VIGIV (vaccinia immune globulin intravenous, human) must be done with a glucose-specific method (monitor and test strips) to avoid interference by maltose contained in VIGIV. […]
Used for
From the label: indications and usageVIGIV (vaccinia immune globulin intravenous, human) is indicated for the treatment and/or modification of the following conditions:
Eczema vaccinatum
Progressive vaccinia
Severe generalized vaccinia
Vaccinia infections in individuals who have skin conditions such as burns, impetigo, varicella-zoster, or poison ivy;
Forms and strengths
Injection.
On the market
- Generic approvals
- No generic approved
- Labelers listed (NDC)
- 1 of which 0 under generic applications, 1 under brand applications, repackagers included
Supply and safety
- Pharmacy cost (NADAC)
- Not in the survey
- Shortage (FDA)
- No current entry
- Recalls by its makers (FDA)
- No recall recorded
- FAERS reports
- 88 through July 30, 2026
What is human vaccinia virus immune globulin used for?
From the label: indications and usageVIGIV (vaccinia immune globulin intravenous, human) is indicated for the treatment and/or modification of the following conditions:
Eczema vaccinatum
Progressive vaccinia
Severe generalized vaccinia
Vaccinia infections in individuals who have skin conditions such as burns, impetigo, varicella-zoster, or poison ivy; or in individuals who have eczematous skin lesions because of either the activity or extensiveness of such lesions
Aberrant infections induced by vaccinia virus that include its accidental implantation in eyes (except in cases of isolated keratitis), mouth, or other areas where vaccinia infection would constitute a special hazard. […]
FDA pharmacologic class: Human Immunoglobulin G.
Source: FDA drug label (CNJ-016), Emergent BioSolutions Canada Inc., effective December 16, 2025 (SPL set a4f9f620-e6e4-4a03-a9a7-79007c8c2cfe), via openFDA; the full label on DailyMed
Is there a generic for human vaccinia virus immune globulin (Cnj)?
No generic human vaccinia virus immune globulin is approved (Drugs@FDA, October 8, 2026).
Source: Drugs@FDA, FDA NDC Directory and the Orange Book (openFDA bulk files, October 8, 2026)
What do FAERS reports show for human vaccinia virus immune globulin?
The FDA Adverse Event Reporting System holds 88 reports that list human vaccinia virus immune globulin among the medicines taken, through July 30, 2026, each a report of something that happened, not proof the medicine caused it; 4 are coded as a death and 10 as a hospital stay. Counts follow how widely a medicine is used and watched, and they are not a measure of how risky it is.
The most reported reactions
Source: FDA Adverse Event Reporting System (FAERS) via openFDA, reports through July 30, 2026
What next?
- Other human immunoglobulin gs
- the pharmacologic class, with prices and generics
- Human vaccinia virus immune globulin side effects
- the label's list beside FAERS reports
- Check an interaction
- what two or more labels say about each other